IL1RL2 and palmoplantar pustulosis: Furthermore, spesolimab, an anti-IL-36 receptor antibody approved for the treatment of generalized pustular psoriasis, was also less effective in patients with PPP (PPPASI-50 at wk 16: 32% of spesolimab-treated versus 23.8% of placebo-treated patients; primary study endpoint not met).26